Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Darlene Dela Cruz"'
Autor:
Nisebita Sahu, Jean-Philippe Stephan, Darlene Dela Cruz, Mark Merchant, Benjamin Haley, Richard Bourgon, Marie Classon, Jeff Settleman
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-10 (2016)
Acquired resistance significantly limits the efficacy of cancer drug therapies. Here, the authors identify miR-371-3p as a suppressor of drug tolerance in cancer cell lines by its target gene PRDX6, which in turn regulates PLA2/PKCα signalling and R
Externí odkaz:
https://doaj.org/article/01cff8d056c9437f9bb6381d87492a43
Autor:
Darlene Dela Cruz, Mark Merchant, Frances Shanahan, Christopher J. Sneeringer, Paul Gibbons, Shiva Malek, Michael Siu, Matthew R. Durk, Weiru Wang, John Moffat, Jianping Yin, Thomas Hunsaker, Liu Wendy, Dennis Leung, Ivana Yen, Charles Eigenbrot, Joachim Rudolph, Christine S Muli, Hank La, Brendan T. Parr, Antonio G. DiPasquale, Malcolm P. Huestis, Alberto Gobbi, Christine Orr
Publikováno v:
Journal of Medicinal Chemistry. 64:3940-3955
Optimization of a series of aryl urea RAF inhibitors led to the identification of type II pan-RAF inhibitor GNE-0749 (7), which features a fluoroquinazolinone hinge-binding motif. By minimizing reliance on common polar hinge contacts, this hinge bind
Autor:
Malcolm P, Huestis, Darlene, Dela Cruz, Antonio G, DiPasquale, Matthew R, Durk, Charles, Eigenbrot, Paul, Gibbons, Alberto, Gobbi, Thomas L, Hunsaker, Hank, La, Dennis H, Leung, Wendy, Liu, Shiva, Malek, Mark, Merchant, John G, Moffat, Christine S, Muli, Christine J, Orr, Brendan T, Parr, Frances, Shanahan, Christopher J, Sneeringer, Weiru, Wang, Ivana, Yen, Jianping, Yin, Michael, Siu, Joachim, Rudolph
Publikováno v:
Journal of medicinal chemistry. 64(7)
Optimization of a series of aryl urea RAF inhibitors led to the identification of type II pan-RAF inhibitor GNE-0749 (
Autor:
Minkyu Jung, Robert Piskol, Amanda R. Moore, Frances Shanahan, Jianping Yin, Hye Sook Han, Yong Sang Hong, Hyeong Seok Lim, Thomas Hunsaker, Darlene Dela Cruz, Zora Modrusan, Liangxuan Zhang, Scott E. Martin, Ehud Segal, Nicholas P. D. Liau, Tae Won Kim, Jeeyun Lee, Christiaan Klijn, Munjeong Choi, Sang Joon Shin, Young Su Noh, Soo Jung Lee, Ivana Yen, Malgorzata Nowicka, Avinashnarayan Venkatanarayan, Yibing Yan, Xin Ye, Shrividhya Srinivasan, Kyu Pyo Kim, Seung Tae Kim, Jin-Soo Kim, Matthew T. Chang, Shiva Malek, Yu Jung Kim, Oakpil Han, Eva Lin, Inhwan Bae, Yoon hee Hong, Jawahar Sudhamsu
Publikováno v:
Nature. 594(7863)
Although RAF monomer inhibitors (type I.5, BRAF(V600)) are clinically approved for the treatment of BRAFV600-mutant melanoma, they are ineffective in non-BRAFV600 mutant cells1–3. Belvarafenib is a potent and selective RAF dimer (type II) inhibitor
Autor:
Mark Merchant, Nisebita Sahu, Richard Bourgon, Marie Classon, Darlene Dela Cruz, Jean-Philippe Stephan, Jeff Settleman, Benjamin Haley
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-10 (2016)
Nature Communications
Nature Communications
Acquired resistance to cancer drug therapies almost always occurs in advanced-stage patients even following a significant response to treatment. In addition to mutational mechanisms, various non-mutational resistance mechanisms have now been recogniz
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.